Working... Menu
Trial record 28 of 59 for:    MLN8237

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02530619
Recruitment Status : Active, not recruiting
First Posted : August 21, 2015
Last Update Posted : February 16, 2018
The Leukemia and Lymphoma Society
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Brady Stein, Northwestern University

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : July 2019
  Estimated Study Completion Date : March 2020